Unjha Formulations Ltd
₹ 11.3
-4.97%
06 Jun
2:16 p.m.
About
Incorporated in 1991, Unjha Formulations Ltd manufactures and sells Isabgol (Psyllium) Ayurvedic formulations.
Key Points
- Market Cap ₹ 5.06 Cr.
- Current Price ₹ 11.3
- High / Low ₹ 20.0 / 8.24
- Stock P/E 18.1
- Book Value ₹ 5.47
- Dividend Yield 0.00 %
- ROCE 17.8 %
- ROE 12.1 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- The company has delivered a poor sales growth of 3.08% over past five years.
- Promoter holding is low: 36.9%
- Company has a low return on equity of 10.1% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Formulations
Loading peers table ...
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
5.87 | 4.92 | 6.56 | 8.84 | 10.36 | 12.23 | 11.30 | 11.28 | 10.59 | 9.96 | 14.16 | 13.15 | |
5.71 | 4.75 | 6.39 | 8.65 | 10.00 | 11.86 | 10.96 | 10.98 | 10.34 | 9.83 | 13.84 | 12.71 | |
Operating Profit | 0.16 | 0.17 | 0.17 | 0.19 | 0.36 | 0.37 | 0.34 | 0.30 | 0.25 | 0.13 | 0.32 | 0.44 |
OPM % | 2.73% | 3.46% | 2.59% | 2.15% | 3.47% | 3.03% | 3.01% | 2.66% | 2.36% | 1.31% | 2.26% | 3.35% |
0.00 | 0.00 | 0.02 | 0.09 | 0.08 | 0.11 | 0.04 | 0.10 | 0.26 | 0.22 | 0.19 | 0.03 | |
Interest | 0.01 | 0.01 | 0.00 | 0.01 | 0.10 | 0.10 | 0.02 | 0.01 | 0.12 | 0.17 | 0.13 | 0.08 |
Depreciation | 0.07 | 0.07 | 0.07 | 0.09 | 0.08 | 0.09 | 0.10 | 0.09 | 0.08 | 0.08 | 0.08 | 0.06 |
Profit before tax | 0.08 | 0.09 | 0.12 | 0.18 | 0.26 | 0.29 | 0.26 | 0.30 | 0.31 | 0.10 | 0.30 | 0.33 |
Tax % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 16.67% | 15.15% |
Net Profit | 0.08 | 0.09 | 0.12 | 0.17 | 0.26 | 0.30 | 0.26 | 0.30 | 0.31 | 0.10 | 0.25 | 0.28 |
EPS in Rs | 0.18 | 0.20 | 0.27 | 0.38 | 0.58 | 0.67 | 0.58 | 0.67 | 0.69 | 0.22 | 0.56 | 0.62 |
Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Compounded Sales Growth | |
---|---|
10 Years: | 10% |
5 Years: | 3% |
3 Years: | 7% |
TTM: | -7% |
Compounded Profit Growth | |
---|---|
10 Years: | 12% |
5 Years: | 1% |
3 Years: | -3% |
TTM: | 12% |
Stock Price CAGR | |
---|---|
10 Years: | 14% |
5 Years: | 3% |
3 Years: | 29% |
1 Year: | 24% |
Return on Equity | |
---|---|
10 Years: | 19% |
5 Years: | 13% |
3 Years: | 10% |
Last Year: | 12% |
Balance Sheet
Figures in Rs. Crores
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
4.48 | 4.48 | 4.48 | 4.48 | 4.48 | 4.48 | 4.48 | 4.48 | 4.48 | 4.48 | 4.48 | 4.48 | |
Reserves | -4.45 | -4.37 | -4.26 | -4.09 | -3.83 | -3.54 | -3.27 | -2.97 | -2.67 | -2.56 | -2.31 | -2.03 |
0.26 | 0.00 | 0.00 | 0.40 | 0.00 | 0.05 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
2.20 | 2.61 | 3.54 | 2.51 | 2.28 | 2.79 | 2.75 | 2.15 | 1.90 | 1.61 | 1.28 | 0.96 | |
Total Liabilities | 2.49 | 2.72 | 3.76 | 3.30 | 2.93 | 3.78 | 3.96 | 3.66 | 3.71 | 3.53 | 3.45 | 3.41 |
1.09 | 1.03 | 1.10 | 1.09 | 1.03 | 1.22 | 1.16 | 1.12 | 1.14 | 1.12 | 1.07 | 1.10 | |
CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
1.40 | 1.69 | 2.66 | 2.21 | 1.90 | 2.56 | 2.80 | 2.54 | 2.57 | 2.41 | 2.38 | 2.31 | |
Total Assets | 2.49 | 2.72 | 3.76 | 3.30 | 2.93 | 3.78 | 3.96 | 3.66 | 3.71 | 3.53 | 3.45 | 3.41 |
Cash Flows
Figures in Rs. Crores
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
2.10 | 0.49 | 0.53 | -0.70 | 0.41 | 0.39 | 0.14 | -0.12 | 0.39 | -0.70 | 0.28 | -0.26 | |
-0.03 | -0.02 | -0.13 | -0.09 | -0.02 | -0.28 | 0.06 | 0.04 | -0.10 | -0.06 | -0.02 | -0.10 | |
-2.07 | -0.27 | -0.02 | 0.40 | -0.40 | 0.05 | -0.05 | 0.23 | 0.00 | 0.00 | 0.00 | -0.06 | |
Net Cash Flow | 0.00 | 0.20 | 0.38 | -0.38 | -0.01 | 0.15 | 0.15 | 0.16 | 0.29 | -0.77 | 0.26 | -0.42 |
Ratios
Figures in Rs. Crores
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 39.80 | 49.71 | 50.63 | 28.08 | 28.54 | 19.40 | 25.19 | 43.36 | 39.64 | 35.91 | 18.04 | 29.14 |
Inventory Days | 23.50 | 39.21 | 50.22 | 35.62 | 22.76 | 40.83 | 39.40 | 22.92 | 21.37 | 55.60 | 34.08 | 39.67 |
Days Payable | 161.57 | 243.64 | 250.41 | 122.48 | 94.35 | 98.20 | 106.22 | 87.50 | 82.79 | 77.35 | 39.81 | 33.40 |
Cash Conversion Cycle | -98.27 | -154.73 | -149.55 | -58.78 | -43.06 | -37.97 | -41.63 | -21.22 | -21.79 | 14.16 | 12.31 | 35.41 |
Working Capital Days | -64.05 | -100.89 | -95.14 | -30.14 | -28.19 | -24.17 | -21.96 | -8.41 | -9.31 | 22.72 | 17.27 | 37.19 |
ROCE % | 7.00% | 50.00% | 72.73% | 37.62% | 50.00% | 47.56% | 25.45% | 22.79% | 25.90% | 14.48% | 21.03% | 17.75% |
Documents
Announcements
- Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A 2 Jun
- Announcement under Regulation 30 (LODR)-Newspaper Publication 16 May
- : Intimation Under Regulation 30 Of SEBI (LODR) Regulations, 2015 ('SEBI Listing Regulations, 2015') - Appointment Of Add. Director 10 May
- Approval Of Audited Financial Results Of The Company For Quarter Ended And Year Ended 31St March,2023 , And Out Come Of Board Meeting Held On 10.05.2023 10 May
- Board Meeting Outcome for Approval Of Audited Financial Results Of The Company For Quarter Ended And Year Ended 31St March,2023 , And Out Come Of Board Meeting Held On 10.05.2023 10 May
Business Profile:[1]
Company is G.M.P. certified for manufacturing & exporting of Isabgol (Psyllium) Ayurvedic formulations products. Company's parent company M/S Urvesh Ltd. is a 100% EOU
which is also engaged in export of
Isabgol Husk & Isabgol Powder.